Display options
Cite
Aggarwal S, Gupta S, Pabla D, et al. Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnol. 2013;4(6):145-157doi: 10.1007/s12645-013-0046-3.
Aggarwal, S., Gupta, S., Pabla, D., & Murthy, R. S. (2013). Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer nanotechnology, 4(6), 145-157. https://doi.org/10.1007/s12645-013-0046-3
Aggarwal, Sahil, et al. "Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer." Cancer nanotechnology vol. 4,6 (2013): 145-157. doi: https://doi.org/10.1007/s12645-013-0046-3
Aggarwal S, Gupta S, Pabla D, Murthy RS. Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnol. 2013;4(6):145-157. doi: 10.1007/s12645-013-0046-3. Epub 2013 Sep 24. PMID: 26069510; PMCID: PMC4452077.
Copy Download .nbib Format: NLM
Share it on

Cancer Nanotechnol. 2013;4(6):145-157. doi: 10.1007/s12645-013-0046-3. Epub 2013 Sep 24.

Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer.

Cancer nanotechnology

Sahil Aggarwal, Swati Gupta, Dilrose Pabla, R S R Murthy

Affiliations

  1. Nanomedicine Research Centre, Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, 142-001 Punjab India.
  2. Nanomedicine Research Centre, Department of Pharmaceutics, I.S.F. College of Pharmacy, Moga, 142-001 Punjab India ; School of Pharmaceutical Sciences, Apeejay Stya University, Sohna-Palwal Road, Sohna-, 122103 Gurgaon (Haryana) India.

PMID: 26069510 PMCID: PMC4452077 DOI: 10.1007/s12645-013-0046-3

Abstract

The aim of the present study was the direct covalent coupling of the epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb) to the surface of poly(lactide)-co-glycolide (PLGA)-polyethylene glycol (PEG) nanoparticles in order to achieve a cell type-specific drug carrier system against pancreatic cancer. The PLGA-PEG-NH

Keywords: Adenocarcinoma; Epidermal growth factor receptor; Gemcitabine; MIA PaCa-2; Multifunctional nanoparticles; Targeting

References

  1. Oncol Rep. 2007 Jul;18(1):151-5 - PubMed
  2. Surg Oncol. 2004 Dec;13(4):201-10 - PubMed
  3. Ann Surg Oncol. 2004 Jul;11(7):644-9 - PubMed
  4. J Ocul Pharmacol Ther. 1996 Spring;12 (1):35-43 - PubMed
  5. EMBO J. 2000 Jul 3;19(13):3159-67 - PubMed
  6. J Control Release. 2001 Apr 2;71(2):203-11 - PubMed
  7. J Control Release. 2002 Feb 19;79(1-3):123-35 - PubMed
  8. Biomaterials. 2009 Oct;30(29):5737-50 - PubMed
  9. Dig Surg. 2006;23(1-2):74-9 - PubMed
  10. J Control Release. 2008 Feb 11;125(3):193-209 - PubMed
  11. Exp Cell Res. 2003 Mar 10;284(1):31-53 - PubMed
  12. J Drug Target. 2008 Jun;16(5):415-23 - PubMed
  13. J Control Release. 1999 Feb 1;57(2):171-85 - PubMed
  14. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 15;848(1):79-87 - PubMed
  15. Nature. 1998 Apr 30;392(6679 Suppl):5-10 - PubMed
  16. Biotechnol Lett. 2010 May;32(5):649-54 - PubMed
  17. Cancer Invest. 1991;9(5):553-62 - PubMed
  18. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7 - PubMed
  19. Biomaterials. 2006 Oct;27(28):4975-83 - PubMed
  20. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Oct 1;74(2):410-4 - PubMed
  21. Mol Cell. 2003 Feb;11(2):507-17 - PubMed

Publication Types